Hydroxyurea at escalated dose versus fixed low‐dose hydroxyurea in adults with sickle cell disease
- 29 November 2023
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 112 (3) , 466-474
Abstract
No abstract availableKeywords
Funding Information
- Food and Drug Administration (R01FD006030)
- National Heart, Lung, and Blood Institute (HL159376)
This publication has 25 references indexed in Scilit:
- Global Burden of Sickle Cell Anaemia in Children under Five, 2010–2050: Modelling Based on Demographics, Excess Mortality, and InterventionsPLOS Medicine, 2013
- Low Dose Hydroxyurea is Effective in Reducing the Incidence of Painful Crisis and Frequency of Blood Transfusion in Sickle Cell Anemia Patients from Eastern IndiaHemoglobin, 2012
- Sickle Cell Disease in AfricaAmerican Journal of Preventive Medicine, 2011
- Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)The Lancet, 2011
- Population Estimates of Sickle Cell Disease in the U.S.American Journal of Preventive Medicine, 2010
- The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)Blood, 2010
- Effective control of sickle cell disease with hydroxyurea therapyIndian Journal of Pharmacology, 2010
- Survival of children with sickle cell diseaseBlood, 2004
- Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell AnemiaNew England Journal of Medicine, 1995
- Prophylaxis with Oral Penicillin in Children with Sickle Cell AnemiaNew England Journal of Medicine, 1986